ProKidney (PROK) Fundamentals 2026 — Revenue Analysis | SniperIQ
ProKidney (PROK) is a US-listed Healthcare company in Biotechnology with a market capitalization of $525M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ProKidney's market cap?
ProKidney (PROK) has a market capitalization of approximately $525M, trading at
How profitable is ProKidney?
ProKidney runs a net profit margin of -8418.0%, a gross margin of -224.4%, and an operating margin of -18959.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ProKidney generate?
ProKidney reported revenue of $893,000 for fiscal year 2025, with net income of -$69M and earnings per share (EPS) of -0.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ProKidney pay a dividend?
ProKidney does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ProKidney financially healthy?
ProKidney carries a debt-to-equity ratio of -0.00x and a current ratio of 9.06x, with a market beta of 1.68. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ProKidney a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ProKidney (PROK) the key facts are: market cap $525M, revenue $893,000, 52-week range 1.525-3.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ProKidney's full fundamentals live
Get ProKidney's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.